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Abstract
Background Besifloxacin ophthalmic suspension 0.6 %
(Besivance; Bausch & Lomb, Rochester, NY, USA) was
approved by the FDA in 2009 for the treatment of bacterial
conjunctivitis, with a recommended 7-day dosing regimen.
Objective The objective of this study was to compare the
safety of besifloxacin ophthalmic suspension 0.6 %, admin-
istered three times a day for 7 days, with that of its vehicle.
Methods This randomized, multicenter, double-masked,
vehicle-controlled, parallel-group study involved 518
patients C1 year of age with a clinical diagnosis of bac-
terial conjunctivitis. Patients were randomized 2:1 to
treatment with besifloxacin 0.6 % ophthalmic suspension
or vehicle, one drop in the infected eye(s) TID for 7 days.
Main outcomes included the incidence and types of adverse
events reported by the subject or observed by the investi-
gator at each study visit.
Results Thirty-one ocular treatment-emergent adverse
events (TEAEs) were reported by 28 subjects in the study
eye; 19 occurred in 17/344 (4.9 %) besifloxacin patients, and
12 occurred in 11/170 (6.5 %) vehicle patients (p = 0.5362).
Only two ocular events (mild instillation site reaction, one
case in each group) were considered ‘‘definitely related’’ to
study treatment. One event of self-limited dysgeusia in the
besifloxacin group was considered definitely related to
treatment; there were no other nonocular TEAEs considered
related to treatment. There were no serious adverse events,
and other safety outcomes (visual acuity, biomicroscopy,
ophthalmoscopy) were unremarkable.
Conclusion These findings indicate that besifloxacin
ophthalmic suspension 0.6 % is safe in patients aged 1 year
and older when used TID for 7 days.
1 Introduction
Besifloxacin ophthalmic suspension 0.6 % (BesivanceTM;
Bausch & Lomb, Rochester, NY, USA) was approved by
the FDA in 2009 for the treatment of bacterial conjuncti-
vitis [1]. The marketed product is formulated with Dura-
Site (InSite Vision Inc., Alameda, CA, USA), a
mucoadhesive polymer delivery system designed to pro-
long the drug’s residence time on the ocular surface, and
facilitate long-acting topical antibacterial activity [2–5].
Besifloxacin is an 8-chlorofluoroquinolone that has an R7-
aminoazepinyl group with broad spectrum in vitro activity
against a wide range of Gram-positive and Gram-negative
ocular pathogens, including multidrug-resistant strains [6–
10]. The mechanism of action of besifloxacin involves
inhibition of bacterial DNA gyrase and topoisomerase IV,
enzymes which are essential for the synthesis and repli-
cation of bacterial DNA [11, 12]. Unlike older fluoro-
quinolones, besifloxacin demonstrates relatively balanced
activity against both DNA gyrase and topoisomerase IV;
this minimizes the likelihood of resistance, which would
require concomitant mutations in both enzymes [11, 12].
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Three large clinical trials have established the safety and
efficacy of besifloxacin ophthalmic suspension 0.6 %
compared with vehicle [13, 14] or active comparator
(moxifloxacin ophthalmic solution 0.5 %) [15] when given
three times a day for 5 days to treat acute bacterial con-
junctivitis. The FDA approved labeling for besifloxacin,
like most other topical ophthalmic antibacterials, recom-
mends a 7-day treatment period for bacterial conjunctivitis
[1]. Because besifloxacin exposure in the efficacy studies
was limited to 5 days, the objective of this study was to
compare safety outcomes associated with besifloxacin
ophthalmic suspension 0.6 %, administered three times a
day for 7 days, with those reported with the use of vehicle
alone.
2 Methods
This study was a multicenter, randomized, double-masked,
vehicle-controlled, parallel-group trial designed to evaluate
the safety of besifloxacin ophthalmic suspension 0.6 %
compared to vehicle in patients with acute bacterial con-
junctivitis. The study involved 24 investigators at 24 sites
across the United States. The protocol was approved by the
institutional review board at each facility, and written,
informed consent was obtained for all subjects prior to
enrollment. For all subjects younger than 18 years of age,
signed consent was required of a legally authorized rep-
resentative; subjects between the ages of 6 and 17 years
also co-signed the consent forms.
The patient inclusion criteria were: age 1 year or
greater; clinical diagnosis of bacterial conjunctivitis as
evidenced by a minimum grade of 1 for both purulent
conjunctival discharge (Scale: 0 = absent; 1 = mild;
2 = moderate; 3 = severe) and bulbar conjunctival injec-
tion (Scale: 0 = normal; 1 = mild; 2 = moderate;
3 = severe) in at least one eye; and pin-hole visual acuity
(VA) equal to or better than 20/200 in both eyes (using age-
appropriate VA testing). All subjects using contact lenses
were instructed to discontinue contact lens wear for the
entire study.
Patient exclusion criteria included: uncontrolled sys-
temic and/or debilitating disease; known hypersensitivity
to besifloxacin, fluoroquinolones, or any component of the
study medication; current or expected treatment with sys-
temic NSAIDs (exception: B81 mg/day of acetylsalicylic
acid), systemic corticosteroids, systemic antihistamines,
systemic antibacterial agents; current or anticipated ocular
therapy (either eye) with any ophthalmic solutions (tear
substitutes, corticosteroids, NSAIDs, mast cell stabilizers,
antihistamines, decongestants, antibacterial agents, immu-
nosuppressant agents); ocular surgery (including laser
surgery), either eye, within 6 weeks prior to study entry;
suspected viral or allergic conjunctivitis; suspected iritis;
history of recurrent corneal erosion syndrome; active
ulcerative keratitis; and compromised immunity.
2.1 Study Treatment and Follow-Up
The subjects were randomized to treatment with besiflox-
acin ophthalmic suspension 0.6 % or vehicle in a 2:1 ratio.
The vehicle was identical to that used for the besifloxacin
formulation without the active ingredient. Both treatments
contained benzalkonium chloride 0.01 %.
Beginning at the first visit (Visit 1, Day 1), subjects
instilled one drop of study treatment in the infected
eye(s) three times daily at approximately 6-h intervals,
continuing through Day 7. If patients with conjunctivitis in
only one eye developed an infection in the other (fellow)
eye during the study treatment period, the subject was
instructed to begin using their study treatment in that eye as
well. All study treatments were collected at visit 2 (Day 8).
Subjects were asked to complete diary records of study
treatment instillation, and medication bottles were also
weighed to assess compliance. The investigators, subjects,
and all other study personnel involved in the monitoring or
conduct of the study were masked to the treatment received.
Cultures of the cul de sac of infected eyes were taken at
each visit, before any treatment was instilled. Subjects
were considered culture confirmed if the colony count (in
CFU/mL) equaled or exceeded the threshold value on the
Cagle list, as modified by Leibowitz [16]. On this list the
threshold is high for species commonly found in healthy
subjects’ eyes (e.g., C1,000 CFU/mL for corynebacteria,
C100 CFU/mL for S. epidermidis), but low for species that
are usually not encountered (e.g., C1 CFU/mL for Pseu-
domonas aeruginosa), thereby reducing the likelihood of
characterizing an infection as culture-confirmed due to the
presence of commensal bacteria. Only one eye from each
subject was designated as the study eye. Study eye deter-
minations were made as follows: For subjects with exactly
one treated eye having at least one pathogenic ocular
bacterial species at or above threshold at baseline and the
minimum required conjunctival discharge and bulbar con-
junctival injection at baseline, the study eye was defined as
that eye. For subjects with both treated eyes having at least
one accepted ocular bacterial pathogen at or above
threshold at baseline and the required conjunctival dis-
charge and bulbar conjunctival injection at baseline, the
study eye was defined as the treated eye with the highest
combined severity of conjunctival discharge and bulbar
conjunctival injection at baseline. If that combined severity
was the same for both eyes, the right eye was considered
the study eye. For subjects whose treated eye(s) did not
have at least one accepted ocular bacterial species at or
above threshold at baseline, the study eye was defined as
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the eye with the highest severity of conjunctival discharge
and bulbar conjunctival injection at baseline, out of the
treated eyes with the required conjunctival discharge and
bulbar conjunctival injection at baseline. If the severity was
the same for both eyes, the right eye was considered the
study eye.
2.2 Outcomes
Study outcomes were assessed on Day 8 (or ?1 day; Visit
2) and Day 11 (±1 day; Visit 3).
2.2.1 Safety
The safety population included all subjects who received at
least one dose of study medication and had at least one
post-treatment safety assessment. The primary safety var-
iable was the incidence of ocular and nonocular treatment-
emergent adverse events (TEAEs). The incidence and type
of TEAEs reported by the subject or observed by the
investigator at each study visit were collected until study
exit. For each TEAE, the investigator assessed the severity
and causality with respect to treatment. Ocular TEAEs
observed in baseline-designated study eyes were of primary
interest and are reported here. Because treatment in fellow
eyes may not have consisted of a full 7 days of exposure,
those data are not included in the primary analysis. Other
safety assessments included changes in visual acuity (VA)
and biomicroscopy and ophthalmoscopy findings.
Age-appropriate VA testing was performed at each visit.
VA was measured through a pin-hole habitual (unaided) or
historical correction using a Snellen chart. For children for
whom Snellen chart testing was inappropriate, the Lea
Symbols or Visual Behavior (fix and follow, wince, and no
wince) was used; VA measurements were attempted in all
children. For any given subject, the same VA testing
method was used at every study visit.
Biomicroscopy was performed at each visit to evaluate
the following: hyperemia and swelling of the lids, chemosis
of the conjunctiva, staining/erosion, edema, and infiltrate of
the cornea, cells and flare in the anterior chamber, lens
opacity, and vitreous pathology all were assessed using a
4-point scale (0 = None, 1 = Mild, 2 = Moderate,
3 = Severe). Direct ophthalmoscopy was performed on
Visits 1 and 3 to assess fundus pathology on a four-point
scale (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe).
2.2.2 Efficacy
Bacterial eradication, an objective indicator of efficacy,
was evaluated in the modified Intent-to-Treat (mITT)
population which included all randomized subjects from
whom baseline cultures indicated bacteria levels at or
above threshold for any accepted ocular bacterial pathogen.
Bacterial eradication, assessed at Visits 2 and 3, was
defined as the absence of all ocular bacterial species
present at or above threshold at baseline. Bacterial eradi-
cation rates were determined for the mITT population
overall and for the subgroup of subjects in the mITT
population with baseline infections with Gram-positive
species, Gram-negative species, and by most prevalent
species.
In the species-specific analysis of bacterial eradication
by most prevalent pathogens, fellow eyes with conjuncti-
vitis severity meeting the study inclusion criteria that
yielded baseline cultures at or above threshold for a species
not present in the study eye were included.
Bacterial eradication rates were reported as observed;
missing or discontinued subjects were not imputed. All
microbial testing was performed at a central laboratory
(Covance Central Laboratory Services, Indianapolis, IN,
USA).
2.3 Data Analysis
2.3.1 Sample Size Determination
Sample size calculations determined that at least 324
subjects were needed in the besifloxacin group to provide a
[95 % probability of detecting TEAEs that occur at a rate
of 1 %, and 162 subjects were needed in the vehicle group
to provide an 80 % probability of detecting TEAEs that
occur at a rate of 1 %. Assuming a 10 % drop-out rate, it
was planned to enroll 540 subjects to yield the minimum
required total of 486 patients.
2.3.2 Statistical Analysis
The primary objective was to determine how the rate of
TEAEs (ocular and nonocular) reported with besifloxacin
ophthalmic suspension 0.6 % used three times daily for
7 days compared with the rate reported with vehicle alone.
Exact 95 % confidence intervals were constructed around
the proportion of subjects and eyes with each TEAE, and
Fisher’s exact test was used to test for differences between




The safety population included 514 subjects: 344 subjects
treated with besifloxacin ophthalmic suspension 0.6 % and
170 subjects treated with vehicle. The mITT population
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included 299 subjects, 212 treated with besifloxacin oph-
thalmic suspension 0.6 % and 87 treated with vehicle. In
both populations, baseline demographics were similar
between treatment groups (Table 1), as was ocular medical
history. In the safety population, pediatric subjects
(B17 years of age) comprised 43.0 and 35.3 % of the
besifloxacin and vehicle groups, respectively.
In the safety population, four subjects in the besifloxacin
treatment group discontinued the study due to a TEAE
[otitis media, worsening of conjunctivitis (2 subjects), and
intervertebral disc protrusion]. All four TEAEs were con-
sidered unrelated/unlikely related to study treatment. In the
vehicle group, four subjects discontinued treatment or
study due to different reasons, including TEAEs: lack of
efficacy and worsening of conjunctivitis, randomization
error and post-traumatic pain, investigator decision and
worsening of conjunctivitis, consent withdrawal and con-
junctivitis. Three of these TEAEs were considered unre-
lated to study treatment and one was considered possibly
related to study drug (lack of efficacy). Other primary
reasons for discontinuation included withdrawal of consent
(n = 1 vehicle group), lost to follow-up (n = 1 besifloxa-
cin group), investigator decision (n = 1 besifloxacin;
n = 3 vehicle), and other reasons (n = 3 besifloxacin;
n = 1 vehicle).
3.2 Compliance
In both the mITT and safety population, the percentage of
patients considered compliant (80–120 % of doses
administered) was C98 % in both treatment groups.
3.3 Exposure to Study Treatment
A total of 344 subjects were exposed to besifloxacin, while
170 subjects were exposed to vehicle (safety population).
Among study eyes, mean ± SD exposure times to study
treatment were similar in the besifloxacin
(6.97 ± 0.39 days) and vehicle (6.92 ± 0.52 days) treat-
ment groups (Table 2). When considering all treated eyes
(study eyes plus any treated fellow eyes), mean ± SD
exposure times were 11.42 ± 3.43 eye-days in the
Table 1 Baseline
demographics of safety and
mITT populations
mITT modified Intent to Treat
population










Mean (SD) 29.6 (25.1) 30.5 (22.5) 27.8 (25.4) 28.5 (21.1)
Range 1–97 1–92 1–97 1–74
Distribution of age categories, n (%)
C1–\2 years 19 (5.5) 8 (4.7) 19 (9.0) 6 (6.9)
2–11 years 107 (31.1) 38 (22.4) 71 (33.5) 21 (24.1)
12–17 years 22 (6.4) 14 (8.2) 9 (4.2) 5 (5.7)
18–29 years 46 (13.4) 29 (17.1) 27 (12.7) 13 (14.9)
30–39 years 30 (8.7) 23 (13.5) 16 (7.5) 13 (14.9)
40–49 years 29 (8.4) 20 (11.8) 17 (8.0) 12 (13.8)
50–59 years 38 (11.0) 20 (11.8) 20 (9.4) 10 (11.5)
C60 years 53 (15.4) 18 (10.6) 33 (15.6) 7 (8.0)
Sex, n (%)
Male 140 (40.7) 75 (44.1) 87 (41.0) 38 (43.7)
Female 204 (59.3) 95 (55.9) 125 (59.0) 49 (56.3)
Racial background, n (%)
American Indian/Alaskan Native 7 (2.0) 3 (1.8) 5 (2.4) 1 (1.1)
Asian 5 (1.5) 5 (2.9) 3 (1.4) 2 (2.3)
Black/African American 83 (24.1) 40 (23.5) 65 (30.7) 30 (34.5)
Native Hawaiian/Pacific Islander 0 1 (0.6) 0 0
White 210 (61.0) 102 (60.0) 121 (57.1) 49 (56.3)
Other 39 (11.3) 19 (11.2) 18 (8.5) 5 (5.7)
Ethnicity, n (%)
Not Hispanic and Not Latino 194 (56.4) 101 (59.4) 126 (59.4) 58 (66.7)
Hispanic or Latino 150 (43.6) 69 (40.6) 86 (40.6) 29 (33.3)
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besifloxacin treatment group and 11.56 ± 3.38 eye-days in
the vehicle treatment group.
3.4 Ocular Treatment-Emergent Adverse Events
(TEAEs)
Overall, 31 ocular TEAEs were reported by 28 subjects in
the study eye (Table 3), with no significant difference
noted between treatment groups. In the besifloxacin group,
19 events were reported in 17/344 (4.9 %) patients; 12
events were reported in 11/170 (6.5 %) vehicle patients
(p = 0.5362). Only two ocular events (one case of instil-
lation site reaction in each of the besifloxacin and vehicle
groups) were considered ‘‘definitely related’’ to study
treatment by the investigator; these events were both con-
sidered mild and resolved without treatment. No subjects
were removed from the study due to these events. One
event of conjunctivitis in the vehicle group was considered
‘‘probably related’’ to treatment. Four TEAEs (punctate
keratitis, instillation site erythema, instillation site pain,
and instillation site reaction) in the besifloxacin group were
considered ‘‘possibly related’’ to treatment, while four
TEAEs (conjunctivitis, conjunctival edema, punctate ker-
atitis, and instillation site irritation) were considered
‘‘possibly related’’ to treatment in the vehicle group. All
study eye ocular events in the besifloxacin group were
considered mild or moderate in severity, while one event
(conjunctivitis) in the vehicle group was considered severe.
Ocular TEAE reported in fellow treated eyes were
similar to those reported in study eyes with 21 events
reported in 18/220 (8.2 %) besifloxacin treated patients and
11 events reported in 11/115 (9.6 %) vehicle treated
patients (p = 0.6855). Consistent with study eyes, one case
of instillation site reaction in each treatment group was
considered ‘‘definitely related’’ to study treatment. Further,
three ocular TEAEs (punctate keratitis, instillation site
erythema, and instillation site reaction) in the besifloxacin
group and two TEAEs (conjunctivitis and instillation site
irritation) in the vehicle group were considered ‘‘possibly
related’’ to treatment. All ocular TEAEs in the fellow
treated eyes were considered mild or moderate in severity.
3.5 Nonocular Treatment-Emergent Adverse Events
(TEAEs)
Overall, 16 nonocular TEAEs were reported by 15 subjects
(Table 4), including 10 events in 9/344 (2.6 %) besifloxa-
cin subjects and six events in 6/170 (3.5 %) vehicle sub-
jects; there was no significant difference in the incidence of
nonocular TEAEs between the two treatment groups
(p = 0.5837). One nonocular event (mild dysgeusia in the
besifloxacin group) was considered definitely related to
treatment; this event resolved without treatment, and the
subject was not discontinued from the study. All other
nonocular events were considered unrelated or unlikely
related to study treatment. No serious AEs were reported or
observed.
3.6 Visual Acuity (VA)
No subject in either treatment group had a reduction in VA
by more than two lines at any visit. Most subjects showed
either an improvement or no change from baseline at Visit
2 (92.1 %, besifloxacin; 96.6 % vehicle) and Visit 3
(93.7 %, besifloxacin; 95.2 %, vehicle). VA findings were
similar for treated fellow eyes.
3.7 Biomicroscopy
Overall, very few subjects (\2 % in either treatment
group) presented treatment emergent biomicroscopy
findings in the study eye at any visit. There were no
significant differences noted between treatment groups for
the frequency of any biomicroscopy findings at Day 8 [6
(1.8 %) besifloxacin subjects vs. 3 (1.8 %) vehicle sub-
jects] or Day 11 [3 (0.9 %) besifloxacin subjects vs. 0
vehicle subjects]. Findings were similar for treated fellow
eyes. Likewise, there were no significant differences
between treatment groups for the specific slit lamp eval-
uations of the eyelid, conjunctiva, cornea, anterior
chamber, lens, or vitreous.
3.8 Ophthalmoscopy
There were no treatment emergent ophthalmoscopy find-
ings on Day 11 in either the study eyes or treated fellow
eyes for either treatment group.
3.9 Bacterial Eradication (Efficacy)
3.9.1 Overall
As expected, at Visit 2 (Day 8), besifloxacin-treated
study eyes had a higher rate of bacterial eradication





n (%) (N = 344)
Vehicle, n (%)
(N = 170)
B6 8 (2.3 %) 5 (2.9 %)
7 332 (96.5 %) 164 (96.5 %)
8–11 4 (1.2 %) 1 (0.6 %)
C12 0 0
Mean ± SD eye days 6.97 ± 0.39 6.92 ± 0.52
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than vehicle-treated study eyes [83.5 % (172/206) vs.
45.0 % (36/80), respectively; Fig. 1a]. A similar pattern
was observed at Day 11, although the difference
between the groups was smaller [84.5 % (169/200) vs.
57.8 % (48/83)].
3.9.2 Eradication of Bacterial Species According to Gram
Stain
Bacterial eradication by baseline infection with either
Gram-positive or Gram-negative species did not differ
Table 3 Ocular treatment-
emergent adverse events
(TEAEs) by investigator
assessment of relationship to
study medication (study eye
only, safety population)
a Includes events considered by
investigator as ‘‘possibly’’,
‘‘probably’’, or ‘‘definitely’’
related; events with unknown
relationship were counted as
‘‘probably related’’






Total number of TEAEs 14 5 6 6
Number of subjects with at least 1 TEAE 13 (3.8 %) 4 (1.2 %) 6 (3.5 %) 5 (2.9 %)
Conjunctivitis 3 (0.9 %) 0 1 (0.6 %) 2 (1.2 %)
Eyelid erythema 2 (0.6 %) 0 0 0
Blepharitis 1 (0.3 %) 0 1 (0.6 %) 0
Corneal infiltrates 1 (0.3 %) 0 0 0
Dacryocystitis 1 (0.3 %) 0 0 0
Eye pain 1 (0.3 %) 0 0 0
Lacrimation increased 1 (0.3 %) 0 0 0
Conjunctival hemorrhage 1 (0.3 %) 0 0 0
Conjunctival edema 1 (0.3 %) 0 0 1 (0.6 %)
Conjunctivitis, allergic 0 0 1 (0.6 %) 0
Punctate keratitis 0 1 (0.3 %) 0 1 (0.6 %)
Scleritis 0 0 1 (0.6 %) 0
Instillation site pain/irritation/erythema 0 2 (0.6 %) 0 1 (0.6 %)
Instillation site reaction 0 2 (0.6 %) 0 1 (0.6 %)
Pain 0 0 1 (0.6 %) 0
Herpes dermatitis 1 (0.3 %) 0 0 0
Post-traumatic pain 0 0 1 (0.6 %) 0
Corneal staining 1 (0.3 %) 0 0 0
Table 4 Nonocular treatment-
emergent adverse events
(TEAEs) by investigator
assessment of relationship to
study medication (safety
population)
a Includes events considered by
investigator as ‘‘possibly’’,
‘‘probably’’, or ‘‘definitely’’
related; events with unknown
relationship were counted as
‘‘probably related’’






Total number of TEAEs 9 1 6 0
Number of subjects with at least 1 TEAE 8 (2.3 %) 1 (0.3 %) 6 (3.5 %) 0
Ear pain 1 (0.3 %) 0 0 0
Dysgeusia 0 1 (0.3 %) 0 0
Pyrexia 1 (0.3 %) 0 0 0
Nasopharyngitis 2 (0.6 %) 0 1 (0.6 %) 0
Otitis media 1 (0.3 %) 0 0 0
Upper respiratory tract infection 1 (0.3 %) 0 0 0
Bronchitis 0 0 1 (0.6 %) 0
Gastroenteritis, viral 0 0 1 (0.6 %) 0
Intervertebral disc protrusion 1 (0.3 %) 0 0 0
Cyst 0 0 1 (0.6 %) 0
Headache 1 (0.3 %) 0 1 (0.6 %) 0
Nasal congestion 1 (0.3 %) 0 0 0
Rhinitis, allergic 0 0 1 (0.6 %) 0
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significantly from overall species. For infections caused by
Gram-positive bacterial species (Fig. 1b), besifloxacin-
treated eyes had a higher rate of bacterial eradication in the
study eye at both Visit 2 and Visit 3 compared to vehicle-
treated eyes. At Visit 2 (Day 8), 82.8 % (135/163) of
besifloxacin-treated eyes had bacterial eradication com-
pared to 38.3 % (23/60) of vehicle-treated eyes. At Visit 3
(Day 11), 84.3 % (134/159) of besifloxacin-treated eyes
had bacterial eradication compared to 54.8 % (34/62) of
vehicle-treated eyes. For Gram-negative bacterial species
(Fig. 1c), besifloxacin-treated eyes also had higher rates of
bacterial eradication at both Visit 2 and Visit 3 than
vehicle-treated eyes. At Visit 2 (Day 8), 91.1 % (72/79) of
besifloxacin-treated eyes had bacterial eradication com-
pared to 71.4 % (20/28) of vehicle-treated eyes. At Visit 3
(Day 11), 89.6 % (69/77) of besifloxacin-treated eyes had
bacterial eradication compared to 75.9 % (22/29) of vehi-
cle-treated eyes.
Results for bacterial eradication for Gram-positive and
Gram-negative bacterial species in the treated fellow eyes
were similar to those for study eyes; besifloxacin-treated
subjects had a higher rate of overall bacterial eradication in
fellow eyes at both Visit 2 and Visit 3 than vehicle-treated
subjects (data not shown).
3.9.3 Eradication of Most Prevalent Species
A total of 528 pathogens were isolated from culture con-
firmed eyes at baseline. The most common species isolated
were Staphylococcus epidermidis (22.0 %), followed by
Haemophilus influenzae (16.7 %), Staphylococcus aureus
(13.1 %), Streptococcus mitis group (10.4 %) and Strep-
tococcus pneumoniae (5.1 %). In the analysis of bacterial
eradication by baseline infection with these species bac-
terial eradication rates were higher with besifloxacin oph-
thalmic suspension compared with vehicle with the
(a) Over all (b) Gram-Positive Species
(c) Gram-Negative Species
Fig. 1 Bacterial eradication
rates in besifloxacin- and
vehicle-treated baseline-
designated study eyes following
TID treatment for 7 days
(modified ITT population). Data
shown for a overall bacterial
species, b Gram-positive
species, and c Gram-negative
species
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exception of Visit 2 for S. pneumoniae and S. mitis group
likely due to the small sample size. Figure 2 presents
bacterial eradication by baseline infection for the four most
prevalent pathogens.
4 Discussion
Results from this large, randomized, double-masked,
vehicle-controlled study, which included 518 subjects from
24 sites across the USA, provides evidence of the safety of
besifloxacin given three times daily for 7 days in the
treatment of bacterial conjunctivitis. The incidences of
nonocular TEAEs and study eye ocular TEAEs were low
and occurred at similar rates for besifloxacin-treated and
vehicle-treated subjects. Ocular events considered at least
possibly related to treatment were reported by only 1.2 %
of besifloxacin-treated subjects and 2.9 % of vehicle-trea-
ted subjects; almost all ocular events were mild or mod-
erate and self-limited. There were no serious adverse
events, and other safety outcomes (visual acuity, biomi-
croscopy, ophthalmoscopy) were unremarkable.
While topical administration of besifloxacin ophthalmic
suspension produces high and prolonged ocular surface
drug concentrations, a previous study found that the aver-
age systemic concentration of besifloxacin after repeated
three times daily dosing was less than 0.5 ng/mL [17]. This
suggests that the risk of systemic side effects after topical
administration of besifloxacin ophthalmic suspensions is
very low. In fact, there was only one nonocular AE (dys-
geusia) in the present study that was considered even
possibly related to treatment (besifloxacin-treated group).
The safety results of this 7-day study are consistent with
previous tolerability findings from three independent
studies of besifloxacin ophthalmic suspension given three
times daily for 5 days [13–15]. A pooled analysis of safety
data from these three clinical studies reported that the most
commonly reported ocular adverse events in besifloxacin-
treated patients were, in order of frequency, blurred vision
(2.1 %), eye pain (1.8 %), eye irritation (1.4 %), con-
junctivitis (1.2 %), and eye pruritus (1.1 %) [18]. Blurred
vision, eye irritation, and conjunctivitis were reported
significantly less frequently by besifloxacin-treated patients
than by patients given vehicle [18]. In the study comparing
besifloxacin and moxifloxacin, eye irritation was signifi-
cantly less common for besifloxacin-treated eyes (0.3 %)
than in moxifloxacin-treated eyes (1.4 %; p = 0.02) [15].
Commonly reported adverse effects with other topical
fluoroquinolones include stinging, chemosis, local irrita-
tion, superficial punctate keratitis, and conjunctival
hyperemia, although more serious events are possible [19].
Overall, the safety results for besifloxacin are comparable,
Fig. 2 Bacterial eradication
rates in species-specific study
eyes following TID treatment
for 7 days with besifloxacin
ophthalmic suspension 0.6 %
(solid lines) or vehicle (dashed
lines) (modified ITT
population). (data shown by
most prevalent species)
250 R. Malhotra et al.
though no serious events were observed in the present
study.
Also consistent with previous studies, bacterial eradi-
cation was seen at a higher rate in besifloxacin-treated eyes
than in vehicle-treated eyes at Day 8 and Day 11, though
the difference between the groups was smaller at Day 11.
This outcome is not unexpected, given the natural course of
the disease. Acute bacterial conjunctivitis is known to be
self-limited in most cases, resolving spontaneously due to
the host’s immune factors in 1–2 weeks [20]. However,
topical ophthalmic antibiotics are warranted as they con-
tribute to hastening clinical resolution and microbiological
remission, decreasing the risk of relapse and the develop-
ment of complications such as keratitis, orbital cellulitis,
and panophthalmitis [21]. A meta-analysis of studies in
which topical antibiotic treatment was compared to placebo
in the management of bacterial conjunctivitis demonstrated
that topical antibiotics were of most benefit in improving
early (Days 2–5) clinical and microbiological remission
rates as opposed to later clinical and microbiological
remission rates (6–10 days) [21]. The treatment effect
(difference between active and vehicle) with besifloxacin
ophthalmic suspension 0.6 % noted at Day 8 in this study
was within the range reported in other studies of topical
antibiotics in the treatment of bacterial conjunctivitis, or
15–39 % at Day 6–10 [22].
In previous studies of besifloxacin ophthalmic suspen-
sion 0.6 % administered TID for 5 days in the treatment of
bacterial conjunctivitis, eradication rates were already very
high at Day 4/5 (91.5 % for besifloxacin vs. 59.7 % for
vehicle [14]; 93.3 % for besifloxacin vs. 91.1 % for
moxifloxacin [15]; and 90.0 % for besifloxacin vs. 46.6 %
for vehicle [13], demonstrating the rapid effect of besi-
floxacin treatment; these bacterial eradication rates were
also associated with rapid improvements in the clinical
signs and symptoms of acute bacterial conjunctivitis. It
follows that although the earliest time point of bacterial
eradication assessment in this study was Day 8, it is likely
that high bacterial eradication rates were achieved much
earlier.
In the present study, similar bacterial eradication rates
were seen at Days 8 and 11 for Gram-positive (82.8 and
84.3 %, respectively) and Gram-negative species (91.1 and
89.6 %, respectively) in besifloxacin-treated eyes. Bacte-
rial eradication rates with vehicle were lower on Days 8
and 11 for both Gram-positive (38.3 and 54.8 %, respec-
tively) and Gram-negative species (71.4 and 75.9 %). The
most common bacterial species isolated at baseline in order
of prevalence were S. epidermidis, H. influenzae, S. aureus,
and S. mitis group. As expected, bacterial eradication rates
for these species also appeared better with besifloxacin
treatment compared with vehicle treatment.
It deserves mention that the besifloxacin ophthalmic
suspension 0.6 % formulation contains the preservative
benzalkonium chloride (BAK) at a concentration of
0.01 %. The presence of BAK in topical ophthalmic for-
mulations has been shown to have dose-dependent con-
junctival and corneal epithelial cell toxicity [23–26],
although the clinical relevance of this phenomenon in
routine clinical practice, especially with short-term usage,
is not yet clear. The very low rate of adverse effects noted
in the current study does not suggest any toxicity risk with
the concentration of BAK present in the besifloxacin sus-
pension formulation. BAK has also been shown to possess
inherent bacteriostatic and bactericidal activities [27, 28];
thus, it is possible that BAK contributed to the bacterial
eradication rate observed in both the besifloxacin treatment
group and vehicle group in the present study, as both
treatments contained BAK at a concentration of 0.01 %.
Since the present study did not include an additional con-
trol group without BAK, any possible confounding of
bacterial eradication rates from the inclusion of BAK
cannot be fully evaluated.
In conclusion, the results of this analysis expand upon
those previously identified using besifloxacin ophthalmic
suspension 0.6 % for 5 days. These new data indicate that
besifloxacin ophthalmic suspension 0.6 % is safe for use in
patients aged 1 year and older with bacterial conjunctivitis
when used TID for 7 days, while providing high bacterial
eradication rates.
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